U.S. pharmaceutical giant Eli Lilly has announced plans to produce its next-generation experimental weight-loss pill, orforglipron, at a newly proposed $6.5 billion manufacturing facility in Texas. The investment marks one of the company’s largest single-site expansions and reflects growing demand for obesity treatments worldwide.
Orforglipron, a once-daily oral GLP-1 receptor agonist, is currently undergoing clinical trials and is part of Lilly’s broader strategy to diversify its obesity and diabetes portfolio. Unlike injectable alternatives, the pill formulation is expected to offer greater convenience and accessibility for patients.
The Texas plant will be equipped with advanced production capabilities to support large-scale manufacturing of orforglipron and other pipeline therapies. Eli Lilly stated that the facility will create thousands of jobs and strengthen domestic pharmaceutical supply chains.
The announcement comes amid surging global interest in weight-loss medications, with analysts projecting multi-billion-dollar market growth in the coming years. Eli Lilly’s move positions the company to compete aggressively in a sector dominated by injectable treatments.
Construction timelines and regulatory milestones for orforglipron remain subject to trial outcomes and FDA approval.
Eli-Lilly-and-Company-Old Hq-Picture.
